Mohammed Afshar
Director/Board Member bij GENOMIC VISION
Profiel
Mohammed Afshar is the founder of Ariana Pharmaceuticals SA, where he holds the title of Chief Executive Officer & Director starting in 2009.
He is also the founder of RiboTargets Ltd.
Dr. Afshar's current job is as a Member-Supervisory Board at Génomic Vision SA, starting in 2022.
His former job was as a Research Fellow at The University of York.
Dr. Afshar's education includes undergraduate, graduate, and doctorate degrees from Université de Montpellier.
Actieve functies van Mohammed Afshar
| Bedrijven | Functie | Begin |
|---|---|---|
| GENOMIC VISION | Director/Board Member | 11-07-2022 |
Ariana Pharmaceuticals SA
 Ariana Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Ariana Pharmaceuticals SA provides pharmaceutical, clinical and data technology. It offers analytics for multi-paramedic data in identifying patient responders to reduce clinical and drug development risk. The firm also develops biomarker signatures to develop processes in anawlyzing multi-paramedic data. The company was founded by Mohammad Afshar in 2003 and is headquartered in Paris, France. | Founder | 01-01-2003 |
Eerdere bekende functies van Mohammed Afshar
| Bedrijven | Functie | Einde |
|---|---|---|
| The University of York | Chief Tech/Sci/R&D Officer | - |
| RiboTargets Ltd. | Founder | - |
Opleiding van Mohammed Afshar
| Université de Montpellier | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GENOMIC VISION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| RiboTargets Ltd. | Health Technology |
Ariana Pharmaceuticals SA
Ariana Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Ariana Pharmaceuticals SA provides pharmaceutical, clinical and data technology. It offers analytics for multi-paramedic data in identifying patient responders to reduce clinical and drug development risk. The firm also develops biomarker signatures to develop processes in anawlyzing multi-paramedic data. The company was founded by Mohammad Afshar in 2003 and is headquartered in Paris, France. | Health Technology |
